Article
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2014
Emmanuel Catherine, Chiew Yoke-Eng, George Joshy, Etemadmoghadam Dariush, Anglesio Michael S, Sharma Raghwa, Russell Peter, Kennedy Catherine, Fereday Sian, Hung Jillian, Galletta Laura, Hogg Russell, Wain Gerard V, Brand Alison, Balleine Rosemary, MacConaill Laura, Palescandolo Emanuele, Hunter Sally M, Campbell Ian, Dobrovic Alexander, Wong Stephen Q, Do Hongdo, Clarke Christine L, Harnett Paul R, Bowtell David D L, deFazio Anna
Abstract excerpt
PURPOSE: Low-grade serous ovarian carcinomas (LGSC) are Ras pathway-mutated, TP53 wild-type, and frequently associated with borderline tumors. Patients with LGSCs respond poorly to platinum-based chemotherapy and may benefit from pathway-targeted agents. High-grade serous carcinomas (HGSC) are TP53-mutated and are thought to be rarely associated with borderline tumors. We sought to determine whether borderline...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.